{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:17Z","timestamp":1791489677627,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":246,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020957","name":"Roche Germany Holding GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010564","name":"German Center for Lung Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101430","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:26:35Z","timestamp":1788963995000},"page":"101430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Frailty, initial attrition and feasibility of novel platinum-free options for advanced non-small-cell lung cancer in the real-world setting"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Cvetkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-8884","authenticated-orcid":false,"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Allg\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriya","family":"Yuskaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kuon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101430_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101430_bib0002","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.21037\/jtd-20-3075","article-title":"Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study","volume":"13","author":"Polanco","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101430_bib0003","doi-asserted-by":"crossref","first-page":"E1497","DOI":"10.21037\/jtd.2016.11.73","article-title":"Treatment dilemma in the care of older adults with advanced lung cancer","volume":"8","author":"Gajra","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101430_bib0004","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.annonc.2025.06.004","article-title":"E. G. C. E. a. Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.ctarc.2026.101430_bib0005","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101430_bib0006","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.21037\/tlcr-24-241","article-title":"Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000 to 2021: a population-based cohort study","volume":"13","author":"Corby","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2026.101430_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_1-4","article-title":"The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly lung cancer Vinorelbine Italian study","volume":"6","author":"Gridelli","year":"2001","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101430_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1054\/bjoc.2000.1304","article-title":"Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer","volume":"83","author":"Beretta","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"9796","key":"10.1016\/j.ctarc.2026.101430_bib0009","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101430_bib0010","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2017.76.8390","article-title":"Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials","volume":"36","author":"Gridelli","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10400","key":"10.1016\/j.ctarc.2026.101430_bib0011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101430_bib0013","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jtho.2025.07.115","article-title":"Brief report: post hoc validation of platinum ineligibility in NSCLC from the phase III IPSOS study","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101430_bib0014","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2147\/CMAR.S361495","article-title":"The age-adjusted Charlson comorbidity index predicts prognosis in elderly cancer patients","volume":"Volume 14","author":"Zhou","year":"2022","journal-title":"Cancer Manage Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101430_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"PsychOther Psychosom."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101430_bib0016","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","article-title":"A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index","volume":"93","author":"Colinet","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101430_bib0017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3000 Heidelberg cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101430_bib0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101430_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921996509","article-title":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer","volume":"13","author":"Magios","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101430_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.670483","article-title":"Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer","volume":"11","author":"Elsayed","year":"2021","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101430_bib0021","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/cncr.29386","article-title":"Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: are patients undertreated?","volume":"121","author":"Sacher","year":"2015","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101430_bib0022","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.2004.02.051","article-title":"Population variations in the initial treatment of non-small-cell lung cancer","volume":"22","author":"Potosky","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101430_bib0023","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3747\/co.27.6049","article-title":"Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101430_bib0024","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101430_bib0025","article-title":"(Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): pr\u00e4vention, diagnostik, therapie und nachsorge des Lungenkarzinoms","volume":"4.0","author":"Deutsche Krebsgesellschaft","year":"2025","journal-title":"Langversion"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101430_bib0026","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus Pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101430_bib0027","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus Crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101430_bib0028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12904-023-01132-5","article-title":"How do cancer patients refuse treatment? A grounded theory study","volume":"22","author":"Khankeh","year":"2023","journal-title":"BMC. Palliat. Care"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101430_bib0029","article-title":"Non-small cell lung cancer patient preferences for first-line treatment: a discrete choice experiment","volume":"5","author":"MacEwan","year":"2020","journal-title":"MDM. Policy. Pract."},{"key":"10.1016\/j.ctarc.2026.101430_bib0030","article-title":"Liquid biopsy of lung cancer before pathological diagnosis is associated with shorter time to treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCo Precis. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101430_bib0031","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jtho.2021.07.008","article-title":"Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort","volume":"16","author":"Dziadziuszko","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101430_bib0032","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101430_bib0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.21037\/tlcr-21-981","article-title":"Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus integrated sequencer","volume":"11","author":"Low","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101430_bib0034","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2217\/imt-2015-0002","article-title":"The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis","volume":"8","author":"Aguiar","year":"2016","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101430_bib0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/CAD.0000000000001118","article-title":"Role of PD-L1 assessment in advanced NSCLC: does it still matter?","volume":"32","author":"Rizzo","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"25","key":"10.1016\/j.ctarc.2026.101430_bib0036","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101430_bib0037","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13063-020-04280-8","article-title":"Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: study protocol of the randomized phase II DURATION trial","volume":"21","author":"Kuon","year":"2020","journal-title":"Trials"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101430_bib0038","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"3rd; et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for high-age patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101430_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101430_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","volume":"11","author":"Daniello","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101430_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ctarc.2026.101430_bib0042","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 systematic review and meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin. Nutr. ESPEN."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101430_bib0043","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/1750743X.2025.2483656","article-title":"Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis","volume":"17","author":"Vitale","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctarc.2026.101430_bib0044","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/DDDT.S560518","article-title":"Infusion-related reactions among cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-013 systematic review and meta-analysis","volume":"Volume 19","author":"Vitale","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101430_bib0045","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study","volume":"34","author":"Corre","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101430_bib0046","article-title":"Risk assessment of heavy metal toxicity induced by platinum accumulation in tumor patients","volume":"13","author":"Zhang","year":"2025","journal-title":"PeerJ."},{"key":"10.1016\/j.ctarc.2026.101430_bib0047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/TACG.S518467","article-title":"A systematic review of SNPs screening for platinum-related pharmacodynamics and pharmacokinetics genes in non-small cell lung cancer for precision medicine","volume":"Volume 18","author":"Afifah","year":"2025","journal-title":"Appl. Clin. Genet."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101430_bib0048","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:46:16Z","timestamp":1791488776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"alternative-id":["S2468294226003400"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101430","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frailty, initial attrition and feasibility of novel platinum-free options for advanced non-small-cell lung cancer in the real-world setting","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101430"}}